AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAY 6 - (NewsRx.com & NewsRx.net) -- FASgen, Inc., announced receipt of a $2.4 million grant award from the National Cancer Institute for phase II of the study of FASgen's novel compounds (fatty acid synthase inhibitors) for their antitumor efficacy in ovarian cancer.
During phase I of this research, FASgen identified six potent small molecule FAS inhibitors that provided a firm scientific basis for formal drug development. These compounds were effective in treating human cancer xenografts in athymic mice, a commonly used preclinical test model.
FASgen has a sponsored research agreement with the Johns Hopkins University (JHU) and is coordinating its research with the JHU Oncology Center.
C-75, the company's index compound, has also produced what the company characterizes as a "remarkable" result in an 18-month study of HER2/neu transgenic female mice that invariably develop FAS-positive breast cancer during the last quarter of their first year. A short course of treatment given to the mice at 12 weeks ...
Source: HighBeam Research, C-75 maker receives $2.4 million grant for cancer drug research.